These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8709350)

  • 1. Familial transitional cell carcinoma.
    Kiemeney LA; Schoenberg M
    J Urol; 1996 Sep; 156(3):867-72. PubMed ID: 8709350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial transitional cell carcinoma among the population of Iceland.
    Kiemeney LA; Moret NC; Witjes JA; Schoenberg MP; Tulinius H
    J Urol; 1997 May; 157(5):1649-51. PubMed ID: 9112497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options.
    Sijmons RH; Kiemeney LA; Witjes JA; Vasen HF
    J Urol; 1998 Aug; 160(2):466-70. PubMed ID: 9679899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism within the cyclin D1 gene is associated with an increased risk of carcinoma in situ in patients with superficial bladder cancer.
    Ito M; Habuchi T; Watanabe J; Higashi S; Nishiyama H; Wang L; Tsuchiya N; Kamoto T; Ogawa O
    Urology; 2004 Jul; 64(1):74-8. PubMed ID: 15245939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
    Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
    J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder.
    Sak SC; Barrett JH; Paul AB; Bishop DT; Kiltie AE
    Br J Cancer; 2005 Jun; 92(12):2262-5. PubMed ID: 15886698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of patients on dialysis with upper urinary tract transitional cell carcinoma.
    Wu CF; Chang PL; Chen CS; Chuang CK; Weng HH; Pang ST
    J Urol; 2006 Aug; 176(2):477-81. PubMed ID: 16813872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract.
    Matsui Y; Utsunomiya N; Ichioka K; Ueda N; Yoshimura K; Terai A; Arai Y
    Urology; 2005 Feb; 65(2):279-83. PubMed ID: 15708038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis.
    Li C; Wu W; Liu J; Qian L; Li A; Yang K; Wei Q; Zhou J; Zhang Z
    Pharmacogenet Genomics; 2006 Apr; 16(4):245-51. PubMed ID: 16538171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular and epidemiological study on bladder cancer: p53 mutations, tobacco smoking, and occupational exposure to asbestos.
    Kannio A; Ridanpää M; Koskinen H; Partanen T; Anttila S; Collan Y; Hietanen E; Vainio H; Husgafvel-Pursiainen K
    Cancer Epidemiol Biomarkers Prev; 1996 Jan; 5(1):33-9. PubMed ID: 8770464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
    Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
    J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial papillary renal cell tumors and subsequent cancers: a nationwide epidemiological study from Sweden.
    Czene K; Hemminki K
    J Urol; 2003 Apr; 169(4):1271-5. PubMed ID: 12629341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.
    Skacel M; Fahmy M; Brainard JA; Pettay JD; Biscotti CV; Liou LS; Procop GW; Jones JS; Ulchaker J; Zippe CD; Tubbs RR
    J Urol; 2003 Jun; 169(6):2101-5. PubMed ID: 12771727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base.
    David KA; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
    J Urol; 2007 Aug; 178(2):451-4. PubMed ID: 17561135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Molecular cytogenetic study of bladder transitional cell carcinoma by FISH].
    Shou J; Wang M; Ma J
    Zhonghua Zhong Liu Za Zhi; 2000 Jan; 22(1):36-8. PubMed ID: 11776593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single-nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances bladder cancer susceptibility.
    Tasci AI; Tugcu V; Ozbek E; Ozbay B; Simsek A; Koksal V
    BJU Int; 2008 Feb; 101(4):503-7. PubMed ID: 17986285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic implications of p53 gene mutations in bladder tumors.
    Lorenzo-Romero JG; Salinas-Sánchez AS; Giménez-Bachs JM; Sánchez-Sánchez F; Escribano-Martínez J; Segura-Martín M; Hernandez-Millán IR; Virseda-Rodríguez JA
    J Urol; 2003 Feb; 169(2):492-9. PubMed ID: 12544295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.